Methods and compositions for the treatment and diagnosis of pain disorders using 9805, 2047, 46566, 57749, 577, 20739, 57145, 1465, 1587, 2146, 2207, 32838, 336 or 52908
AssigneeMillennium Pharmaceuticals, Inc.
InventorsInmaculada Silos-Santiago, Julie Rosenfeld
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for the treatment and diagnosis of pain disorders. The invention further provides methods for identifying a compound capable of treating a pain disorder. In addition, the invention provides a method for treating a subject having a pain disorder, e.g., a pain disorder characterized by aberrant 9805, 2047, 46566, 57749, 577, 20739, 57145, 1465, 1587, 2146, 2207, 32838, 336 and 52908 polypeptide activity or aberrant 9805, 2047, 46566, 57749, 577, 20739, 57145, 1465, 1587, 2146, 2207, 32838, 336 and 52908 nucleic acid expression.
Claims16
A method for identifying a candidate compound capable of treating a pain disorder, comprising:
- i) combining a compound to be tested with a host cell expressing a polypeptide selected from the group consisting of:
- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 4, 7, 10, 14, 17, 20, 23, 26, 29, 32, 35, 38 or 41;
- b) a polypeptide comprising an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO:2, 4, 7, 10, 14, 17, 20, 23, 26, 29, 32, 35, 38 or 41;
- c) a polypeptide encoded by the nucleotide sequence set forth in SEQ ID NO:1, 3, 5, 6, 8, 9, 11, 12, 13, 15, 16, 18, 19, 21, 22, 24, 25, 27, 28, 30, 31, 33, 34, 36, 37, 39 or 40;
- and
- d) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, 3, 5, 6, 8, 9, 11, 12, 13, 15, 16, 18, 19, 21, 22, 24, 25, 27, 28, 30, 31, 33, 34, 36, 37, 39 or 40;
- under conditions suitable for binding of the test compound to the polypeptide;
- and
- ii) detecting binding of the test compound to the polypeptide to thereby identify a compound which binds to the polypeptide;
- thereby identifying a compound capable of treating a pain disorder.
A method for identifying a candidate compound capable of modulating a pain signaling mechanism comprising:
- i) combining a compound to be tested with a host cell expressing a polypeptide selected from the group consisting of:
- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 4, 7, 10, 14, 17, 20, 23, 26, 29, 32, 35, 38 or 41;
- b) a polypeptide comprising an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO:2, 4, 7, 10, 14, 17, 20, 23, 26, 29, 32, 35, 38 or 41;
- c) a polypeptide encoded by the nucleotide sequence set forth in SEQ ID NO:1, 3, 5, 6, 8, 9, 11, 12, 13, 15, 16, 18, 19, 21, 22, 24, 25, 27, 28, 30, 31, 33, 34, 36, 37, 39 or 40;
- and
- d) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, 3, 5, 6, 8, 9, 11, 12, 13, 15, 16, 18, 19, 21, 22, 24, 25, 27, 28, 30, 31, 33, 34, 36, 37, 39 or 40;
- under conditions suitable for binding of the test compound to the polypeptide;
- and
- ii) detecting binding of the test compound to the polypeptide to thereby identify a compound which binds to the polypeptide;
- thereby identifying a compound capable of modulating a pain signaling mechanism.
A method for identifying a compound capable of treating a pain disorder or capable of modulating a pain signaling mechanism, comprising:
- i) combining a compound to be tested with a host cell expressing a polypeptide selected from the group consisting of:
- a) a polypeptide comprising the amino acid sequence of SEQ ID NO:2, 4, 7, 10, 14, 17, 20, 23, 26, 29, 32, 35, 38 or 41;
- b) a polypeptide comprising an amino acid sequence which is at least 95% identical to the amino acid sequence of SEQ ID NO:2, 4, 7, 10, 14, 17, 20, 23, 26, 29, 32, 35, 38 or 41;
- c) a polypeptide encoded by the nucleotide sequence set forth in SEQ ID NO:1, 3, 5, 6, 8, 9, 11, 12, 13, 15, 16, 18, 19, 21, 22, 24, 25, 27, 28, 30, 31, 33, 34, 36, 37, 39 or 40;
- and
- d) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:1, 3, 5, 6, 8, 9, 11, 12, 13, 15, 16, 18, 19, 21, 22, 24, 25, 27, 28, 30, 31, 33, 34, 36, 37, 39 or 40;
- and
- ii) assaying the ability of the test compound to modulate the expression of a 9805, 2047, 46566, 57749, 577, 20739, 57145, 1465, 1587, 2146, 2207, 32838, 336 and 52908 nucleic acid or the activity of a 9805, 2047, 46566, 57749, 577, 20739, 57145, 1465, 1587, 2146, 2207, 32838, 336 and 52908 polypeptide, thereby identifying a compound capable of treating a pain disorder or capable of modulating a pain signaling mechanism.
A method for treating a subject having a pain disorder characterized by aberrant 9805, 2047, 46566, 57749, 577, 20739, 57145, 1465, 1587, 2146, 2207, 32838, 336 and 52908 polypeptide activity or aberrant 9805, 2047, 46566, 57749, 577, 20739, 57145, 1465, 1587, 2146, 2207, 32838, 336 and 52908 nucleic acid expression comprising administering to the subject a 9805, 2047, 46566, 57749, 577, 20739, 57145, 1465, 1587, 2146, 2207, 32838, 336 and 52908 modulator, thereby treating said subject having a pain disorder.
Dependencies are inferred from the claim text.